礼来公司近期披露，其在对复合型替尔泊肽仿制药的持续监测中，再度发现多项重大安全隐患。除先前已通报的问题外，最新检测结果显示部分仿制药样本存在细菌污染及内毒素含量严重超标等致命缺陷。
此次发现进一步凸显了非正规渠道流通的替尔泊肽仿制药可能对患者健康构成的潜在威胁。公司强调，这些未经严格质控的仿制产品不仅无法保证疗效，更可能引发不可预测的用药风险。
业内专家指出，该事件再次敲响生物制剂合规生产的警钟。随着糖尿病治疗需求的持续增长，确保此类高风险药物全链条质量监管已成为行业当务之急。
礼来公司近期披露，其在对复合型替尔泊肽仿制药的持续监测中，再度发现多项重大安全隐患。除先前已通报的问题外，最新检测结果显示部分仿制药样本存在细菌污染及内毒素含量严重超标等致命缺陷。
此次发现进一步凸显了非正规渠道流通的替尔泊肽仿制药可能对患者健康构成的潜在威胁。公司强调，这些未经严格质控的仿制产品不仅无法保证疗效，更可能引发不可预测的用药风险。
业内专家指出，该事件再次敲响生物制剂合规生产的警钟。随着糖尿病治疗需求的持续增长，确保此类高风险药物全链条质量监管已成为行业当务之急。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.